Skip Navigation



Annals of Oncology Advance Access published online on November 4, 2009
Annals of Oncology, doi:10.1093/annonc/mdp488
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Laé, M.
Right arrow Articles by Vieillefond, A.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Laé, M.
Right arrow Articles by Vieillefond, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press [on behalf of the European Society for Medical Oncology].
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.5/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Assessing HER2 gene amplification as a potential target for therapy in invasive urothelial bladder cancer with a standardized methodology: results in 1005 patients

M. Laé1,*, J. Couturier2, S. Oudard3, F. Radvanyi4, P. Beuzeboc5 and A. Vieillefond6

1 Departments of Pathology
2 Departments of Genetics, Institut Curie
3 Department of Medical Oncology, Hôpital Européen Georges Pompidou
4 Medical Recherche Unit 144-Oncologie Moléculaire-Centre national de la recherche scientifique, Institut Curie
5 Department of Medical Oncology, Institut Curie
6 Department of Pathology, Hôpital Cochin, Paris, France

* Correspondence to: Dr M. Laé, Department of Pathology, Institut Curie, 26 rue d'Ulm, 75231 Paris cedex 05, France. Tel: +33-1-44-32-42-54; Fax: +33-1-44-32-40-72; E-mail: marick.lae{at}curie.net

Background: This study assessed the human epidermal growth factor receptor-2 (HER2) protein expression and its relationship with gene amplification in invasive bladder carcinoma, using the same criteria than for breast cancer.

Patients and methods: In 1005 patients, paraffin-embedded tissues of transurethral resection or cystectomy were evaluated by immunohistochemistry (IHC), using antibodies against HER2. All samples with a 2+ or 3+ HER2 overexpression were evaluated by FISH.

Results: HER2 overexpression was observed in 93 (9.2%) tumors (2+: 42 tumors and 3+: 51 tumors). Using FISH, all HER2 3+ tumors had a gene amplification, whereas no amplification was found in 2+ tumors. Intratumoral heterogeneity was observed in 35% of cases. These tumors showed the same heterogeneous pattern, with adjacent 3+ positive and negative areas by both IHC and FISH.

Conclusions: This study showed that 5.1% of invasive bladder carcinomas had a HER2 gene amplification. These findings may have clinical implications for the management of patients with HER2-positive locally advanced or metastatic bladder cancer, as they could be potential candidates for targeted therapy.

FISH, HER2, immunohistochemistry, targeted therapy, urothelial bladder carcinoma

Received for publication June 14, 2009. Revision received August 6, 2009. Accepted for publication September 17, 2009.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.